YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented...
Hence then, the article about remegen announces exciting results of telitacicept phase 3 clinical trial for patients with generalized myasthenia gravis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis )
Also on site :
- Gil Mora, un chico entre gigantes que deslumbra con México en el Mundial 2026 y que tiene destino europeo
- Fireworks light up New York City to mark 250 years of US independence
- Storm threat triggers chaotic evacuation ahead of Trump’s speech (VIDEOS)